Page last updated: 2024-09-05

erlotinib hydrochloride and Aberrant Crypt Foci

erlotinib hydrochloride has been researched along with Aberrant Crypt Foci in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arcilla, M; Benya, R; Bhattacharya, A; Carroll, R; Chen, WP; Chung, J; Gillen, DL; Gonzalez, R; Huang, Z; Lipkin, SM; Meyskens, FL; Mo, A; Morgan, TR; Rodriguez, LM; Rosenberg, DW; Szabo, E; Tucker, C; Wong, V; Zell, JA	1

Trials

1 trial(s) available for erlotinib hydrochloride and Aberrant Crypt Foci

Article	Year
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:3 Topics: Aberrant Crypt Foci; Case-Control Studies; Colorectal Neoplasms; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Rectum; Signal Transduction	2015

Article

Year

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:3

Topics: Aberrant Crypt Foci; Case-Control Studies; Colorectal Neoplasms; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Rectum; Signal Transduction

2015